• Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

  NCT01822080

  CompletedInterventionalPhase 3Updated Nov 25, 2015
• A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

  NCT05560646

  CompletedInterventionalPhase 2Updated May 8, 2026
• The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis

  NCT05476172

  CompletedInterventionalNot ApplicableUpdated Jul 21, 2023
• Efficacy and Safety of SH T00660AA in Treatment of Endometriosis

  NCT00225199

  CompletedInterventionalPhase 3Updated Apr 23, 2010
• Efficacy and Safety Study of Elagolix in Women With Endometriosis

  NCT00973973

  CompletedInterventionalPhase 2Updated Sep 26, 2018
• Endometriosis Trial: Study of NBI-56418 in Endometriosis

  NCT00109512

  CompletedInterventionalPhase 2Updated Feb 22, 2012

ClinicalTrials.gov ID

NCT07164183

Lead Sponsor

AlceaOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

290Estimated

Last Update Posted

Sep 18, 2025Actual

Start Date

Sep 11, 2025Actual

Primary Completion Date

Oct 2026Estimated

Completion Date

Nov 2026Estimated

Official Title

Prospective, Multicenter, Open-label, Randomized, Parallel Groups Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules (LLC Alcea, Russia) and Visanne 2 mg Tablets (BAYER AG, Germany) in Treatment of Endometriosis

Brief Summary

Prospective open-label randomized parallel groups study to compare efficacy and safety of Indinol Forto® 200 mg capsules and Visanne 2 mg tablets in treatment of endometriosis. This is phase 3 study, based on hypothesis of non-inferiority.

Detailed Description

Prospective open-label randomized parallel groups study to compare efficacy and safety of Indinol Forto® 200 mg capsules and Visanne 2 mg tablets in treatment of endometriosis. This is phase 3 study, based on hypothesis of non-inferiority.

The study population consists of females from 18 to 45 years old inclusively at the moment of screening who have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis within not more than 60 months and not less than 2 weeks of study entry, and reported at least moderate pelvic pain within minimum 2 months of study entry.

Study participants are observed during 1 menstrual cycle during screening period (Screening Cycle). Participants who meet inclusion criteria and don't meet exclusion criteria will be randomly assigned to one of two treatment arms (Group 1: Indinol Forto® 200 mg capsules two times per day or Group 2: Visanne 2 mg tablets once per day). After observation on treatment during 24 weeks (monthly Visits 1-7) the study subjects enter post-treatment period and are observed for one more month (Post-Treatment Period, Visit 8).

Visual Analog Scale (VAS) is used in the study as the main tool for assessment of daily pelvic pain. Cyclic and non-cyclic pain, as well as intensity of vaginal bleeding are assessed daily during the study.

The study primary efficacy endpoint is the change in average daily pelvic pain score (cyclic and non-cyclic, combined) during the 6th treatment period (interval between Visit 6 and Visit 7) in comparison to the Screening period.

• Endometriosis

• Indole-3-carbinol
• Dienogest

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. The participant provides written informed consent for participation in the study in accordance with current legislation.
2. Female participants in reproductive/premenopausal period from 18 to 45 years old inclusively (at the moment of signing informed consent).
3. Participants have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis (ICD code #80) within not more than 60 months and not less than 2 weeks of study entry, stage I-III according to endometriosis revised classification of American Fertility Society (R-AFS, 1985)).
4. Participant has had spontaneous, (i.e., without hormonal therapy) regular, menstrual cycles with a cycle length between 24 to 38 days (inclusive) for the past 2 cycles before Visit 0 and during screening period.
5. Participant has no current indications for surgical treatment of endometriosis.
6. Participant has had endometriosis-related pelvic pain assessed with visual analogue scale (VAS) and defined as average daily pain score ≥3.5 cm during 2 menstrual cycles prior to screening (assessed by the participant retrospectively at the moment of screening) and during screening menstrual cycle (according to the data from the participant's diary completed daily).
7. Presence of other symptoms of endometriosis (e.g. dysmenorrhea, dyspareunia, dyschezia, data of ultrasound imaging, or magnetic resonance imaging (MRI).
8. The participant agrees to use highly effective contraception methods described in the protocol from the time of signing informed consent through the whole duration of the study and for 2 months after the study completion.
9. Negative pregnancy test.
10. Participant completed daily diary on minimum 75% of days during screening menstrual cycle.

Exclusion Criteria:

1. Presence of contraindications to Indinol Forto (indolcarbinol)
2. Presence of contraindications to Visanne (dienogest)
3. Participant had undiagnosed (unexplained), abnormal, vaginal or urinary tract bleeding within the past 6 months before screening (Visit 0).
4. Participant has chronic pelvic pain not caused by endometriosis, but other gynecological or urological disorders (consequences of inflammatory process, uterine fibroids, pelvic congestion syndrome, etc.).
5. Participant has chronic, non-pelvic pain not caused by endometriosis that requires chronic analgesic or other chronic therapy (including, but not limited to, fibromyalgia, chronic back pain or chronic headaches).
6. Endometrioid cysts ≥ 3 cm.
7. Participant has a surgical history of hysterectomy and/or bilateral oophorectomy; premature ovarian failure. Note: Participants who have undergone surgical sterilization (eg, bilateral salpingectomy, tubal ligation) are permitted in the trial.
8. Participant has a clinically significant gynecologic condition identified in the screening evaluation including, but not limited to, ovarian cysts larger than 3 cm and present longer than 4 months, an active sexually transmitted disease, etc. Note: Participants may be rescreened after completing treatment for infection or for simple ovarian cysts.
9. Participant with endometriosis-related pelvic pain who didn't respond to previous treatment with combined oral contraceptives, GnRH agonists or antagonist, progestins or aromatase inhibitors. Note: Participants who demonstrated partial response or interrupted their treatment due to side effects, may be enrolled in the study.
10. History of malignancy, including suspected malignization of endometriomas within ≤5 years before signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
11. Severe renal failure (glomerular filtration rate calculated with Cockcroft-Gault formula is below 30 ml/min/1,73 m2).
12. Systolic blood pressure >160 mm Hg or diastolic blood pressure >90 mm Hg during screening period.
13. Clinically significantly abnormal laboratory tests at Screening, including: alkaline phosphatase (AP), alanine aminotransferase (ALT, SGPT), aspartate aminotransferase (AST, SGOT) >200% of the upper limit of normal, or total bilirubin >150% of the upper limit of normal; hemoglobin <10 g/dl, white blood cell count <2500 in mm³, neutrophil count <1500 in mm³, platelet count <100 х 10³/mm³.
14. Hyperthyroidism (TSH below 0.4 mU/L) or hypothyroidism (TSH above 4.0 mU/L).
15. Positive pregnancy test (including pregnancy within 3 months prior to screening) or lactation period.
16. Other medical conditions that, in the judgment of the Investigator, may increase the risk associated with study participation or may interfere with the interpretation of study results.
17. History of alcohol or substance abuse.
18. Participation in a clinical study within 90 days before screening.
19. Other reasons that, in the judgment of the Investigator, may interfere with participation in the study or may lead to unreasonable risks.
20. Conditions requiring surgery in the period of the study.
21. Conditions requiring therapy prohibited by the study protocol.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

AlceaOTHER

kirill.sokolov@alceapharma.ru7-495-502-9247